|
Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study. |
| |
|
Consulting or Advisory Role - 4D Pharma; AADi; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; CG Oncology; Dyania Health; EMD Serono; Fresenius Kabi; G1 Therapeutics; Gilead Sciences; Guardant Health; ImmunityBio; Janssen; Lucence; Merck; Pfizer; PureTech; Roche; Seagen; Silverback Therapeutics; Strata Oncology; Urogen pharma |
Research Funding - Acrivon Therapeutics (Inst); ALX Oncology (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst) |
| |
|
|
Consulting or Advisory Role - AstraZeneca; AVEO; Bayer; BMS; Caris Life Sciences; Dendreon (Inst); Eisai; EMD Serono; Exelixis; Pfizer |
Speakers' Bureau - AstraZeneca; Bayer (Inst); Caris Life Sciences (Inst); Merck; Pfizer/Astellas (Inst) |
Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Exelixis; Merck (Inst); Pfizer (Inst) |
| |
|
Honoraria - EMD Serono; Pfizer/EMD Serono |
Research Funding - Amgen (Inst); Apollomics (Inst); Arcus Biosciences (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); HUYA Bioscience International (Inst); Nektar (Inst); Prometheus; Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Seagen (Inst); Xenocor |
Travel, Accommodations, Expenses - Aveo; Bayer; Seagen |
| |
|
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb/Medarex; EMD Serono; Foundation Medicine; Gilead Sciences; Merck; Pfizer; Seagen |
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Janssen Oncology; Seagen |
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst) |
| |
|
Employment - Texas Oncology |
Honoraria - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer |
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer |
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Pfizer (Inst) |
| |
|
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Foundation Medicine; Genzyme; Gilead Sciences; Immunomedics; IMPAC Medical Systems; Incyte; Janssen Oncology; Medscape; Merck; MSD; Pfizer; Roche; UroToday |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - Abbvie; EPI-Q; Johnson & Johnson; Lilly |
Research Funding - Acceleron Pharma; Amolyt Pharma; Bristol-Myers Squibb; ChemoCentryx; Janssen Scientific Affairs; Merck; MSD; Neurocrine Biosciences; Pfizer; Seagen; Sunovion; United Therapeutics |
| |
|
Employment - EMD Serono; Merck KGaA |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
|
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
Stock and Other Ownership Interests - Merck |
| |
|
|
| |
|
|
Stock and Other Ownership Interests - Merck |
Travel, Accommodations, Expenses - Merck |
| |
|
Employment - Myriad Genetics (I) |
|
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; Bristol-Myers Squibb; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Lucence; Merck; Pfizer; Scholar Rock; Seagen; Syapse; Vial |
Speakers' Bureau - Exelixis; Gilead Sciences; INFORMAÇÃO BRASILEIRA DE ONCOLOGIA; Medscape; Natera; Onclive; Physicans' Education Resource; Research to Practice; Seagen |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); GeneCentric (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Predicine (Inst); QED Therapeutics (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
Other Relationship - Astellas Pharma; Bristol-Myers Squibb; Elsevier; G1 Therapeutics; Mereo BioPharma; QED Therapeutics |